Skip to content

Timothy D Brewerton

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.

3 papers in the library · 486 citations · publishing 2013-2022

Papers

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.

Journal of psychopharmacology (Oxford, England) January 1, 2013 Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer et al. 377 citations

In a long-term follow-up of the first completed trial of MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD, all 19 original participants took part, and 16 completed all outcome measures 17 to 74 months after their final MDMA session (average 45.4 months). The mean CAPS score at follow-up (23.7) was nearly identical to the mean score at study exit (24.6), indicating that the substantial symptom relief achieved during the trial was maintained over time. Although two participants relapsed, the majority sustained clinically significant improvements, and no one reported harm from participation.

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.

Journal of psychiatric research May 1, 2022 Timothy D Brewerton, Julie B Wang, Adele Lafrance et al. 81 citations

Among 89 individuals with severe PTSD enrolled in a placebo-controlled trial of MDMA-assisted therapy, 15% had eating disorder symptoms in the clinical range and 31.5% in the high-risk range at baseline, despite no active purging or low weight. After treatment, participants who received MDMA-assisted therapy showed significantly greater reductions in eating disorder symptoms compared to those who received placebo, especially among women with elevated baseline scores. The findings suggest that eating disorder psychopathology is common in severe PTSD and that MDMA-assisted therapy may reduce these co-occurring symptoms.

The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD.

Medical hypotheses January 1, 2021 Timothy D Brewerton, Adele Lafrance, Michael C Mithoefer 28 citations

Eating disorders remain difficult to treat, especially when accompanied by posttraumatic stress disorder. MDMA-assisted psychotherapy for treatment-resistant PTSD shows promise, with two-thirds of participants achieving full remission at one year or more follow-up. The authors hypothesize this therapy will be effective for both eating disorder and PTSD symptoms in people with both conditions. MDMA's effects—reduced fear, enhanced wellbeing, increased sociability, reduced self-criticism, increased compassion, interpersonal trust, and alert consciousness—may counteract avoidance and hyperarousal in therapy. Other features like body image distortion, cognitive rigidity, and socio-emotional difficulties may also improve. Personal accounts describe benefit, but risks and challenges are noted.